

## Special Issue

# Personalized Therapy of Sarcomas

### Message from the Guest Editors

Sarcomas are a group of rare malignant mesenchymal tumors, which differ in primary tumor location at almost any anatomical site, age at diagnosis, treatment, and prognosis. Over 70 different histological subtypes exist. This presents a number of challenges with regards to providing adequate personalized treatment and care, as well as in the setup of adequate clinical trials. So far, patients with sarcomas did not benefit from major breakthroughs in the oncology field, for example immunotherapy. Thus, this Special Issue highlights the personalized therapy of sarcomas. Personalized medicine takes into account molecular and biological heterogeneity, encouraging preclinical assessments in adequate models, smart clinical trial designs and clinical endpoints that matter for patients and their loved ones.

### Guest Editors

Dr. Christian Rothermundt

Kantonsspital St. Gallen, 9007 St. Gallen, Switzerland

Dr. Ingrid M. E. Desar

Radboud University Medical Center, Nijmegen, The Netherlands

### Deadline for manuscript submissions

closed (15 April 2024)



## Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/133612](https://mdpi.com/si/133612)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)